Home

Corvia has announced completion of randomisation in its REDUCE LAP-HF II global, pivotal trial. The trial is evaluating the Corvia atrial shunt (IASD)—a novel, transcatheter implant—to reduce elevated left atrial pressures (LAP), the primary cause of HF symptoms, in heart failure patients with preserved ejection fraction (HFpEF) or mid-range ejection fraction (HFmrEF). The company also announced authorisation by the US Food and Drug Administration (FDA) to continue evaluation of the Corvia Atrial Shunt under a Continued Access Protocol (CAP) while its pre-market approval (PMA) application is under review. PMA submission is planned for late 2021.

REDUCE LAP-HF II is a large, prospective, multicentre, randomised, sham-controlled trial to evaluate interatrial shunting. The study randomised 626 patients at 109 sites across 15 countries, with the aim to improve quality of life, reduce HF symptoms and decrease HF-related hospitalisations. Primary outcome measures will be evaluated after the last randomised patient completes 12-month follow-up. Sanjiv Shah from Northwestern University Feinberg School of Medicine, Chicago, US, and Martin Leon, from the Columbia University Irving Medical Center, New York, USA serve as lead principal investigators.

“The outcome of the landmark REDUCE LAP-HF II trial has the potential to revolutionise how we treat these heart failure patients, which is the greatest unmet need in cardiology today,” stated Shah. “Treating this population is challenging, and often frustrating, because standard treatments for heart failure don’t work well. Data from this study evaluating the efficacy of the Corvia Atrial Shunt will provide valuable information regarding this novel therapy in this underserved patient population.”

Leon added: “In light of the increasing incidence of heart failure, innovative treatment options are of critical importance. We are pleased with the study execution and enrolment pace of this trial, and are eagerly awaiting the results, which have the potential to change the treatment paradigm for heart failure.”

“Randomising the last pivotal trial patients is a significant milestone for Corvia and brings us one step closer to providing this innovative technology to patients in the USA,” said George Fazio, president and CEO of Corvia Medical. “REDUCE LAP-HF II is one of the largest randomised heart failure device trials ever undertaken and demonstrates our commitment to building a strong body of clinical evidence showing how atrial shunting advances care for patients suffering with the debilitating symptoms of heart failure.”

Corvia also announced FDA authorisation to continue patient enrolment under a CAP. The open label REDUCE LAP-HF IV study will enrol patients at existing pivotal trial centres. “We are pleased to have the opportunity to continue to offer this breakthrough therapy to heart failure patients,” said Jan Komtebedde, senior vice president and chief medical officer at Corvia Medical. “In collaboration with our advisors and investigators, we are committed to generating unbiased evidence to support this new therapeutic class of atrial shunting for heart failure. This study provides an opportunity to generate additional safety and efficacy evidence to support future therapy adoption.”

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Corvia completes randomisation in REDUCE LAP-HF II trial

Chia sẽ qua google bài: Corvia completes randomisation in REDUCE LAP-HF II trial

Chia sẽ qua twitter bài: Corvia completes randomisation in REDUCE LAP-HF II trial

Chia sẽ qua MySpace bài: Corvia completes randomisation in REDUCE LAP-HF II trial

Chia sẽ qua LinkedIn bài: Corvia completes randomisation in REDUCE LAP-HF II trial

Chia sẽ qua stumbleupon bài: Corvia completes randomisation in REDUCE LAP-HF II trial

Chia sẽ qua icio bài: Corvia completes randomisation in REDUCE LAP-HF II trial

Chia sẽ qua digg bài: Corvia completes randomisation in REDUCE LAP-HF II trial

Chia sẽ qua yahoo bài: Corvia completes randomisation in REDUCE LAP-HF II trial

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.